PMID- 14515722
OWN - NLM
STAT- MEDLINE
DCOM- 20031125
LR  - 20131121
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 61
IP  - 9
DP  - 2003 Sep
TI  - [Mini-transplantation from HLA-mismatched donors].
PG  - 1549-54
AB  - Bone marrow transplantation(BMT) from genotypically human leukocyte antigen 
      (HLA)-matched siblings improves long-term survival in patients with hematologic 
      malignancies. However, more than 70% of patients who could benefit from 
      allogeneic BMT do not have a matched sibling donor. Furthermore, allogeneic BMT 
      has been limited to young patients because of the increased risk for 
      regimen-related toxicity and graft-versus-host disease(GVHD) that occurs with 
      increasing age. HLA-haploidentical minitransplantation may solve these problems. 
      In minitransplants using a preconditioning regimen consisting of fludarabine, 
      busulfan and anti-T-lymphocyte globulin and a GVHD prophylaxis of tacrolimus and 
      methylprednisolone, we showed that minitransplantation from HLA-haploidentical 
      related donors was possible.
FAU - Ogawa, Hiroyasu
AU  - Ogawa H
AD  - Department of Molecular Medicine, Osaka University Graduate School of Medicine.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - FA2DM6879K (Vidarabine)
RN  - G1LN9045DK (Busulfan)
RN  - P2K93U8740 (fludarabine)
SB  - IM
MH  - Animals
MH  - Antilymphocyte Serum/therapeutic use
MH  - *Bone Marrow Transplantation
MH  - Busulfan/therapeutic use
MH  - Graft vs Host Disease/prevention & control
MH  - *HLA Antigens
MH  - Hematologic Neoplasms/therapy
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - *Transplantation Conditioning
MH  - Transplantation, Homologous
MH  - Vidarabine/*analogs & derivatives/therapeutic use
RF  - 15
EDAT- 2003/10/01 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/10/01 05:00
PHST- 2003/10/01 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/10/01 05:00 [entrez]
PST - ppublish
SO  - Nihon Rinsho. 2003 Sep;61(9):1549-54.